Why the study?
Does bupropion improve long-term smoking cessation rates compared to placebo or nicotine replacement therapy?
Does bupropion improve long-term smoking cessation rates compared to placebo or nicotine replacement therapy?
Answers are grounded in this paper and cite their sources.
Bupropion is an effective, affordable pharmacological therapy that should be integrated into primary care to aid smoking cessation.
The association between hypertension and a “hardening” of the pulse and apoplexy has been recognised for hundreds of years. The major problem in elderly people is isolated systolic hypertension, defined as a raised systolic pressure but normal diastolic pressure. It affects around half of people aged over 60 years.1 Originally, because isolated systolic hypertension was so common it was considered part of ageing and, like essential hypertension, benign. However, there is now compelling evidence from cross sectional, longitudinal, and randomised controlled trials that show that isolated systolic hypertension confers a substantial cardiovascularrisk.2 3 Despite this, it remains underdiagnosed and largely untreated.4 The roots of this lie in a century of overreliance on the importance of diastolic pressure and largely unjustified concerns about the potential adverse consequences of treating systolic pressure. After the mercury sphygmomanometer …
No takes yet. Share an insight, caveat, or question.
Ian B. Wilkinson (2000) conducted an editorial in Smoking. Bupropion vs. Placebo or transdermal nicotine was evaluated on Smoking cessation sustained for one year.
Synapse has enriched 10 related papers. Consider them for comparative context: